Breaking News

Novella Clinical Names Reg Affairs Director

January 29, 2013

Kelso brings extensive device experience

Karen Kelso, Ph.D., has been named regulatory affairs director, focused on cardiovascular medical devices, at Novella Clinical. Dr. Kelso has extensive regulatory experience in global markets for all medical device classifications (I, IIa, IIb and III).
 
Dr. Kelso will drive regulatory and clinical strategy for multinational programs. She has achieved numerous CE Marks and has written, submitted, and cleared multiple 510(k)s with the FDA. Her experience also includes several pre-IDE submissions and IDE approvals.
 
Dr. Kelso joins the company after 16 years with Vascutek, a Terumo Company in Scotland, where she most recently served as vice president regulatory affairs and clinical studies for the company’s portfolio of vascular products. She previously held positions in R&D.
 
Novella Clinical’s Global Head of Regulatory Affairs, Kevin Johnson, said, “Karen’s regulatory experience in the U.S., Europe and Asia and her relationships with international agency officials will greatly benefit Novella’s medical device clients, many of whom are seeking to expand clinical trials to international markets.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research